Long-term complications in patients with chronic hypoparathyroidism: a cross-sectional study

in European Journal of Endocrinology
Correspondence should be addressed to B Decallonne; Email: brigitte.decallonne@uzleuven.be
Restricted access


Chronic hypoparathyroidism and its treatment may lead to symptoms and complications affecting quality of life. We determined complications in chronic hypoparathyroid patients.


Retrospective cross-sectional study of patients with chronic hypoparathyroidism treated with active vitamin D supplements in a tertiary care centre during the year 2015. Primary outcome parameters were history of kidney stones and seizures and presence of renal and cerebral calcifications on imaging. Secondary outcome parameters were current symptoms of paraesthesia/cramps, hospitalization due to hyper/hypocalcaemia and hypercalciuria.


One hundred and seventy patients were included – 143 (84%) with post-surgical hypoparathyroidism (PSHP), 16 (9%) with non-surgical hypoparathyroidism (NSHP) and 11 (7%) with pseudo-hypoparathyroidism (PHP).


History of kidney stones and seizures was present in 15 and 9% of patients, respectively. Renal and cerebral imaging was performed in 51 and 26% of the patients, with 22 and 25% of these patients having renal and cerebral calcifications respectively. Both history of seizures and cerebral calcifications were significantly more in NSHP and PHP than in PSHP patients. No association was observed between seizures and cerebral calcifications. Cramps/paraesthesia were present in 16%, and hospitalization related to hypocalcaemia was reported in 5% of the patients. Calciuria was screened in 47% at the time of consultation, and in 76% of the patients during the past 5 years. In 36% of these patients, calciuria was increased.


Patients with chronic hypoparathyroidism frequently develop ectopic calcifications. Non-surgical patients suffer more from seizures and cerebral calcifications than patients that developed hypoparathyroidism post surgery. There is a need for increased screening of long-term complications, according to the guidelines.


     European Society of Endocrinology

Related Articles

Article Information


All Time Past Year Past 30 Days
Abstract Views 735 735 123
Full Text Views 92 92 6
PDF Downloads 54 54 5



  • View in gallery

    Identification of patients with chronic hypoparathyroidism.



ShobackD. Clinical practice. Hypoparathyroidism. New England Journal of Medicine 2008 359 391403. (https://doi.org/10.1056/NEJMcp0803050)


BilezikianJPKhanAPottsJTJrBrandiMLClarkeBLShobackDJüppnerHD’AmourPFoxJRejnmarkL et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. Journal of Bone and Mineral Research 2011 26 23172337. (https://doi.org/10.1002/jbmr.483)


ClarkeBLBrownEMCollinsMTJüppnerHLakatosPLevineMAMannstadtMMBilezikianJPRomanischenAFThakkerRV. Epidemiology and diagnosis of hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism 2016 101 22842299. (https://doi.org/10.1210/jc.2015-3908)


ShobackDMBilezikianJPCostaAGDempsterDDralleHKhanAAPeacockMRaffaelliMSilvaBCThakkerRV et al. Presentation of hypoparathyroidism: etiologies and clinical features. Journal of Clinical Endocrinology and Metabolism 2016 101 23002312. (https://doi.org/10.1210/jc.2015-3909)


UnderbjergLSikjaerTMosekildeLRejnmarkL. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. Journal of Bone and Mineral Research 2013 8 22772285. (https://doi.org/10.1002/jbmr.1979)


UnderbjergLSikjaerTMosekildeLRejnmarkL. The epidemiology of nonsurgical hypoparathyroidism in Denmark: a Nationwide case finding study. Journal of Bone and Mineral Research 2015 30 17381744. (https://doi.org/10.1002/jbmr.2501)


UnderbjergLSikjaerTMosekildeLRejnmarkL. Pseudohypoparathyroidism – epidemiology, mortality and risk of complications. Clinical Endocrinology 2016 84 904911. (https://doi.org/10.1111/cen.12948)


ClarkeBLLeibsonCEmersonJRansomJELagastH. Co-morbid medical conditions associated with prevalent hypoparathyroidism: a population-based study. Journal of Bone and Mineral Research 2011 26 (Supplement 1) (Abstract SA1070).


BilezikianJPBrandiMLCusanoNEMannstadtMRejnmarkLRizzoliRRubinMRWinerKKLibermanUAPottsJTJr. Management of hypoparathyroidism: present and future. Journal of Clinical Endocrinology and Metabolism 2016 101 23132324. (https://doi.org/10.1210/jc.2015-3910)


AbateEGClarkeBL. Review of hypoparathyroidism. Frontiers in Endocrinology 2017 7 172. (https://doi.org/10.3389/fendo.2016.00172)


UnderbjergLSikjaerTRejnmarkL. Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study. Journal of Bone and Mineral Research 2018 33 822831. (https://doi.org/10.1002/jbmr.3368)


AlmquistMIvarssonKNordenströmEBergenfelzA. Mortality in patients with permanent hypoparathyroidism after total thyroidectomy. British Journal of Surgery 2018 105 13131318. (https://doi.org/10.1002/bjs.10843)


BollerslevJRejnmarkLMarcocciCShobackDMSitges-SerraAvan BiesenWDekkersOM. European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults. European Journal of Endocrinology 2015 173 G1G20. (https://doi.org/10.1530/EJE-15-0628)


StackBCJrBimstonDNBodennerDLBrettEMDralleHOrloffLAPallotaJSnyderSKWongRJ et al. American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: postoperative hypoparathyroidism – definitions and management. Endocrine Practice 2015 21 674685. (https://doi.org/10.4158/EP14462.DSC)


LeveyASStevensLASchmidCHZhangYLCastroAF3rdFeldmanHIKusekJWEggersPVan LenteFGreeneT et al. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine 2009 150 604612. (https://doi.org/10.7326/0003-4819-150-9-200905050-00006)


MitchellDMReganSCooleyMRLauterKBVrlaMCBeckerCBBurnett-BowieSAMannstadtM. Long-term follow-up of patients with hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism 2012 97 45074514. (https://doi.org/10.1210/jc.2012-1808)


LopesMPKliemannBSBiniIBKulchetschkiRBorsaniVSaviLBorbaVZMoreiraCA. Hypoparathyroidism and pseudohypoparathyroidism: etiology, laboratory features and complications. Archives of Endocrinology and Metabolism 2016 60 532536. (https://doi.org/10.1590/2359-3997000000221)


ArltWFremereyCCalliesFReinckeMSchneiderPTimmermannWAllolioB. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. European Journal of Endocrinology 2002 146 215222. (https://doi.org/10.1530/eje.0.1460215)


UnderbjergLSikjaerTRejnmarkL. Health-related quality of life in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism. Clinical Endocrinology 2018 88 838847. (https://doi.org/10.1111/cen.13593)


VokesTJMannstadtMLevineMAClarkeBLLakatosPChenKPiccoloRKrasnerAShobackDMBilezikianJP. Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism 2018 103 722731. (https://doi.org/10.1210/jc.2017-01471)


KuboderaN. A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol. Molecules 2009 14 38693880. (https://doi.org/10.3390/molecules14103869)


HalabeAArieRMimranDSamuelRLibermanUA. Hypoparathyroidism – a long-term follow-up experience with 1-alpha-vitamin D3 therapy. Clinical Endocrinology 1994 40 303307. (https://doi.org/10.1111/j.1365-2265.1994.tb03923.x)


OkanoKFurukawaYMoriiHFujitaT. Comparative efficacy of various vitamin D metabolites in the treatment of various types of hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism 1982 55 238243. (https://doi.org/10.1210/jcem-55-2-238)


StreetenEAMohtasebiYKonigMDavidoffLRyanK. Hypoparathyroidism: less severe hypocalcemia with treatment with vitamin D2 compared to calcitriol. Journal of Clinical Endocrinology and Metabolism 2017 102 15051510. (https://doi.org/10.1210/jc.2016-3712)


MannstadtMClarkeBLVokesTBrandiMLRanganathLFraserWDLakatosPBajnokLGarceauRMosekildeL et al. Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomized, phase 3 study. Lancet Diabetes and Endocrinology 2013 1 275283. (https://doi.org/10.1016/S2213-8587(13)70106-2)


LakatosPBajnokLLagastHValkuszZ. An open-label extension study of parathyroid hormone RHPTH(1–84) in adults with hypoparathyroidism. Endocrine Practice 2016 22 523532. (https://doi.org/10.4158/EP15936.OR)


AndrewsEBGilsenanAWMidkiffKSherrillBWuYMannBHMasicaD. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and finding from the first 7 years. Journal of Bone and Mineral Research 2012 27 24292437. (https://doi.org/10.1002/jbmr.1768)


StoneMDHoskingDJGarcia-HimmelstineCWhiteDARosenblumDWorthHG. The renal response to exogenous parathyroid hormone in treated pseudohypoparathyroidism. Bone 1993 14 727735. (https://doi.org/10.1016/8756-3282(93)90204-N)


GoswamiRSharmaRSreenivasVGuptaNGanapthyADasS. Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism. Clinical Endocrinology 2012 77 200206. (https://doi.org/10.1111/j.1365-2265.2012.04353.x)


AggarwalSKailashSSagarRTripathiMSreenivasVSharmaRGuptaNGoswamiR. Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium. European Journal of Endocrinology 2013 168 895903. (https://doi.org/10.1530/EJE-12-0946)

Cited By


Google Scholar